Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objectives Facial and genital plaques are common manifestations of psoriasis, are challenging to treat, and significantly impact patients’ quality of life (QoL).Methods GULLIVER is a prospective, non-interventional study conducted in 2020–2023 in Italy, aimed at examining the effectiveness, safety and QoL impact of guselkumab through 52 weeks of treatment in patients with facial and/or genital psoriasis. The primary endpoint was the percentage of patients achieving a static Physician Global Assessment (sPGA) score of ≤1 and a minimum 2-grade improvement in sPGA score at Week 52.Results Of 351 enrolled patients, 88.6% remained on guselkumab treatment at Week 52. The proportions of patients achieving the sPGA targets in the facial and genital groups, respectively, were 83.3% and 76.5% at week 12, increasing to 93.8% and 97.9% at Week 52. Mean Dermatology Life Quality Index score improved from 12.0 ± 7.5 at baseline to 1.1 ± 2.0 at Week 52 for patients with facial psoriasis (p-value <0.001) and from 12.0 ± 6.9 to 1.6 ± 3.5 for those with genital psoriasis (p-value <0.001). Guselkumab was well-tolerated and no new safety signals were identified.Conclusions This Italian real-world study demonstrated the high effectiveness and a good safety profile of guselkumab in treating facial and genital psoriasis.
Authors: Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, Antonio Giovanni Richetta, Marco Romanelli, Francesca Satolli, Monica Corazza, Laura Atzori, Claudia Lasagni, Concetta Potenza, Paola Savoia, Federico Bardazzi, Vito Giuseppe Di Lernia, Marco Galluzzo, Matteo Megna, Claudia Giofrè, Leonardo Zichichi, Claudio Guarneri, Sabatino Pallotta, Maria Concetta Fargnoli, Francesco Loconsole, Annamaria Offidani, Martina Burlando, Stefano Piaserico, Ketty Peris, Manuela Papini, Carlo Giovanni Carrera, Francesca Prignano, Maria Rita Bongiorno, Paolo Dapavo, Luca Stingeni, Massimo Donini, Giuseppe Micali, Franco Rongioletti, Giuseppe Stinco, Federico Saibene, Talia Gramiccia, Antonio Costanzo
Institutions: San Gallicano Hospital, University of Campania "Luigi Vanvitelli", University of Salerno, Sapienza University of Rome, University of Pisa, University of Parma, University of Ferrara, University of Cagliari, Azienda Ospedaliero-Universitaria di Modena, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Rome Tor Vergata, Policlinico Tor Vergata, Federico II University Hospital, University of Naples Federico II, University of Messina, Istituto Dermopatico dell'Immacolata, University of L'Aquila, University of Bari Aldo Moro, Marche Polytechnic University, Ospedale Policlinico San Martino, University of Genoa, University of Padua, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, University of Perugia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Florence, University of Palermo, University of Catania, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, University of Udine, Johnson & Johnson (United States), IRCCS Humanitas Research Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
Funders: Johnson and Johnson, Cilag
OpenAlex ID: W7128053208